SCYNEXIS, Inc. (LON:0L49)

Market Cap	32.12M
Revenue (ttm)	6.39M
Net Income (ttm)	-27.19M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92
Average Volume	2,558
Open	1.115
Previous Close	1.115
Day's Range	1.110 - 1.115
52-Week Range	0.985 - 3.070
Beta	n/a
RSI	46.60
Earnings Date	Mar 28, 2025

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 29
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L49

Financial Performance

Financial numbers in USD